Navigation Links
Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
Date:8/29/2007

Misfolded Protein Diagnostic (MPD) Shown to be Sensitive and Specific Technology Applicable for the Detection of a Host of Amyloid Neurological

Diseases including Creutzfeldt-Jakob Disease (CJD), Alzheimer's, and

Parkinson Disease

ROCKVILLE, Md., Aug. 29 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today the publication of a study, "Detection of misfolded prion protein in blood with conformationally sensitive peptides," in the August 2007 issue of the journal Transfusion. The monthly publication is the official peer-reviewed journal of the AABB, formerly known as the American Association of Blood Banks.

The published study examined the ability of Adlyfe's Misfolded Protein Diagnostic (MPD) to detect the presence of misfolded proteins in brain, serum and plasma. Study results demonstrated that Adlyfe's MPD assay is a sensitive and specific test for the detection misfolded prion proteins that may be useful in both preclinical and clinical diagnosis transmissible spongiform encephalopathy (TSE) diseases in both animals and humans.

Scientists have tried to develop a preclinical diagnostic test for TSE since the discovery that humans with variant Creutzfeldt-Jakob disease can transmit disease via blood transfusions, though there are several challenges to detecting misfolded proteins in the blood. The coexistence of a large amount of the protein in its normally folded shape and the fact that misfolded proteins do not trigger an immune system response that would enable diagnosis based on the detection of antibodies. In addition, most standard detection methods are not sensitive enough to detect the low level of misfolded proteins in the blood, especially during early disease stages. These challenges have largely restricted diagnostic tests for amyloid diseases to the use of postmortem tissue.

Adlyfe's novel technology is based on the synthesis of conformationally sensitive peptides (chains of amino acids that are smaller than proteins) which are created to target specific protein shapes associated with various diseases. The interaction of the target protein with Adlyfe's proprietary peptides produces a conformational change that transduces a fluorescent signal. Further amplification of the signal is generated as additional ligands undergo conformational changes. This is the basis for the tests' sensitivity and ability to detect very low amyloid protein levels before symptoms occur.

"The publication of this study validates the utility and sensitivity of our MPD assay in detecting misfolded proteins in TSE, even at low levels," said Chief Executive Officer Alan S. Rudolph, Ph.D. "We believe our test meets the dual diagnostic demands of confirmatory testing in symptomatic subjects suspected of having the disease and as a screening test to identify infection in its earliest phases. Our unique diagnostic approach and technology is applicable to a number of neurological diseases associated with protein buildup in tissues such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease."

About Adlyfe

Adlyfe Inc. was established early in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain and amyloid diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease, Huntington's disease, systemic amyloidosis, diabetes and other diseases.

The Company's novel technology is based on the synthesis of small peptide, or Pronucleon(TM) ligands, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid aggregation (and eventual amyloid plaque formation). These aggregates are associated with disease state progression in a number of brain-wasting and amyloid diseases.

Adlyfe, a privately-held corporation, was initially funded by the Defense Advanced Research Projects Agency (DARPA), the U.S. Army Medical Research and Materiel Command, the National Heart, Lung and Blood Institute, and Britain's Department for Environment, Food and Rural Affairs. More recently, Adlyfe raised additional funding with venture capital firms Canaan Venture Partners and Burrill Associates.

Internet Website: http://www.adlyfe.com

For More Information

Media:

Janine McCargo

1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Adlyfe
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 IRIDEX Corporation (Nasdaq: IRIX ... for the fourth quarter and 2016 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... infarction partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605670-summary/view-report.html Description The ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/22/2017)... , Feb. 22, 2017 Merrimack Pharmaceuticals, Inc. ... will host its Fourth Quarter 2016 investor conference call and ... The call will cover an update on ... quarter and full year 2016 financial results. A press release ... be issued the morning of Wednesday, March 1. Investors and ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... Dallas, TX (PRWEB) , ... ... ... HCC Risk Adjustment solution leverages advanced data analytics to accurately understand each ... ensure proper reimbursement for a given population. This new solution helps transform ...
(Date:2/22/2017)... ... ... Doctors on Liens is continuing its steady expansion of medical specialties throughout ... North Valley Eye Medical Group in Mission Hills . Eye injuries and vision ... cases. These injuries have a major impact on the quality of life of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the ... simple online checklist. Over a period of just 24 months, thousands of individuals interested ... online checklist called T.A.D. , “The internet is not getting quieter. In fact it’s ...
Breaking Medicine News(10 mins):